Form 4: Boston Scientific EVP Arthur Butcher Reports Stock Transactions
SEC Form 4 Filing
Arthur C. Butcher, EVP & Group President at Boston Scientific, reports the exercise of stock options and sale of shares under a pre-established 10b5-1 trading plan.
Summary
- Arthur C. Butcher, an Executive Vice President at Boston Scientific, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On May 1, 2025, Butcher exercised stock options to acquire a total of 17,314 shares at prices ranging from $17.26 to $27.09.
- The same day, Butcher sold 17,314 shares at a weighted average price of $102.0551.
- These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
- Following these transactions, Butcher directly owns 22,235 shares of Boston Scientific common stock and indirectly owns 13,360 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions under a pre-existing plan. There's no indication of positive or negative sentiment towards the company's performance.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. The use of a pre-established 10b5-1 trading plan suggests that these transactions were planned in advance and not based on any recent material non-public information.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the medical device industry.
- Companies like Medtronic and Abbott also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
- There is no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/22/2017 | First anniversary of stock option grant. |
| 06/01/2017 | First anniversary of stock option grant. |
| 02/28/2018 | First anniversary of stock option grant. |
| 02/15/2019 | First anniversary of stock option grant. |
| 08/09/2024 | Date of adoption of Rule 10b5-1 trading plan. |
| 05/01/2025 | Date of stock option exercise and sale. |
| 05/05/2025 | Date of Form 4 filing. |
| 02/22/2026 | Expiration date of stock options. |
| 06/01/2026 | Expiration date of stock options. |
| 02/28/2027 | Expiration date of stock options. |
| 02/15/2028 | Expiration date of stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Rule 10b5-1, Boston Scientific, BSX, Butcher, Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.